Virucidal efficacy of different formulations for hand and surface disinfection targeting SARS CoV-2.


Journal

The Journal of hospital infection
ISSN: 1532-2939
Titre abrégé: J Hosp Infect
Pays: England
ID NLM: 8007166

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 06 11 2020
revised: 19 02 2021
accepted: 01 03 2021
pubmed: 28 3 2021
medline: 8 6 2021
entrez: 27 3 2021
Statut: ppublish

Résumé

In the ongoing SARS CoV-2 pandemic, effective disinfection measures are needed, and guidance based on the methodological framework of the European Committee for Standardization (CEN) may enable the choice of effective disinfectants on an immediate basis. This study aimed to elucidate whether disinfectants claiming 'virucidal activity against enveloped viruses' as specified in the European Standard EN 14476 as well as in the German Association for the Control of Viral Diseases/Robert Koch Institute (DVV/RKI) guideline are effectively inactivating SARS-CoV-2. Two commercially available formulations for surface disinfection and one formulation for hand disinfection were studied regarding their virucidal activity. Based on the data of this study the enveloped SARS-CoV-2 is at least equally susceptible compared to the standard test virus vaccinia used in the EN 14476 and DVV/RKI guidelines. Thus, chemical disinfectants claiming 'virucidal activity against enveloped viruses' based on the EN 14476 and DVV/RKI guidelines will be an effective choice to target enveloped SARS-CoV-2 as a preventive measure.

Identifiants

pubmed: 33771601
pii: S0195-6701(21)00112-2
doi: 10.1016/j.jhin.2021.03.015
pmc: PMC7986349
pii:
doi:

Substances chimiques

Antiviral Agents 0
Disinfectants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-30

Informations de copyright

Copyright © 2021 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Auteurs

K Steinhauer (K)

Department Research & Scientific Services, Schülke & Mayr GmbH, Norderstedt, Germany; Faculty of Mechanical Engineering, Kiel University of Applied Sciences, Kiel, Germany. Electronic address: katrin.steinhauer@schuelke-mayr.com.

T L Meister (TL)

Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.

D Todt (D)

Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany; European Virus Bioinformatics Center, Jena, Germany.

A Krawczyk (A)

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

L Paßvogel (L)

Department Research & Scientific Services, Schülke & Mayr GmbH, Norderstedt, Germany.

B Becker (B)

Dr. Brill + Partner GmbH Institut for Hygiene and Microbiology, Hamburg, Germany.

D Paulmann (D)

Dr. Brill + Partner GmbH Institut for Hygiene and Microbiology, Hamburg, Germany.

B Bischoff (B)

Dr. Brill + Partner GmbH Institut for Hygiene and Microbiology, Hamburg, Germany.

M Eggers (M)

Labor Prof. Gisela Enders MVZ GbR, Stuttgart, Germany.

S Pfaender (S)

Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.

F H H Brill (FHH)

Dr. Brill + Partner GmbH Institut for Hygiene and Microbiology, Hamburg, Germany.

E Steinmann (E)

Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH